SCHEMBL4589173

SCHEMBL4589173

CCNC(=O)N1CCCN(c2ccc(C(=O)OC)cc2[N+](=O)[O-])CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MAPT P10636 10/20 0.56
GAA P10253 2/20 0.56
CYP1A2 P05177 3/20 0.55
CYP2D6 P10635 3/20 0.55
CYP2C9 P11712 3/20 0.55
CYP2C19 P33261 3/20 0.55
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
POLB P06746 2/20 0.54
KMT2A Q03164 4/20 0.52
LMNA P02545 1/20 0.52
HTT P42858 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
MAPK1 P28482 1/20 0.52
RECQL P46063 1/20 0.51
MEN1 O00255 3/20 0.50
CYP3A4 P08684 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5322691 0.83 KDM4E (0.67) ALDH1A1MAPTGAAKDM4EHPGD
SCHEMBL105883 0.83 MAPT (0.56) ALDH1A1MAPTGAACYP1A2CYP2D6
SCHEMBL195322 0.83 ALDH1A1 (0.70) ALDH1A1MAPTGAACYP1A2CYP2D6
SCHEMBL13979594 0.82 CXCR3 (0.49) KDM4ESMN1; SMN2KMT2ANPSR1
SCHEMBL4289177 0.79 WDR5 (0.69) ALDH1A1MAPTGAACYP1A2CYP2D6
SCHEMBL14334390 0.79 MAPT (0.59) ALDH1A1MAPTGAACYP1A2CYP2D6
SCHEMBL4589191 0.79 MAPT (0.59) ALDH1A1MAPTGAACYP1A2CYP2D6
SCHEMBL13979165 0.78 CXCR3 (0.71)
SCHEMBL4589478 0.78 ALDH1A1 (0.51) ALDH1A1MAPTGAAKDM4EHPGD
SCHEMBL14377108 0.78 MAPT (0.63) ALDH1A1MAPTGAACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312215-A1 Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-12-18 US disclosed
US-20080312215-A1 Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-12-18 US disclosed
WO-2007002742-A1 SUBSTITUTED [1,4]-DIAZEPANES AS CXCR3 ANTAGONISTS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS PHARMACOPEIA, INC. (US) 2007-01-04 WO disclosed
WO-2007002742-A1 SUBSTITUTED [1,4]-DIAZEPANES AS CXCR3 ANTAGONISTS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS PHARMACOPEIA, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312215-A1 Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders CXCR3, CXCR1, CX3CR1 ALDH1A1 1053/4885MAPT 4702/4885GAA 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.